Nevro (NVRO) Retained Earnings : $-724.8 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Nevro Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Nevro's retained earnings for the quarter that ended in Mar. 2024 was $-724.8 Mil.

Nevro's quarterly retained earnings declined from Sep. 2023 ($-690.4 Mil) to Dec. 2023 ($-699.4 Mil) and declined from Dec. 2023 ($-699.4 Mil) to Mar. 2024 ($-724.8 Mil).

Nevro's annual retained earnings increased from Dec. 2021 ($-624.2 Mil) to Dec. 2022 ($-607.2 Mil) but then declined from Dec. 2022 ($-607.2 Mil) to Dec. 2023 ($-699.4 Mil).

Nevro Retained Earnings Historical Data

The historical data trend for Nevro's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nevro Retained Earnings Chart

Nevro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-409.77

-492.83

-624.19

-607.20

-699.41

Nevro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-642.23	-666.95	-690.43	-699.41	-724.82

Nevro Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Nevro (NYSE:NVRO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Nevro (NVRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (NYSE:NVRO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

1N7:Germany

Address

1800 Bridge Parkway, Redwood City, CA, USA, 94065

Website

https://www.nevro.com

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Executives

Greg Siller	officer: Chief Commercial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Shawn Mccormick	director	9600-54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55441
Kevin R Thornal	officer: President & CEO	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard B. Carter	officer: Chief Accounting Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Kashif Rashid	officer: General Counsel	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
D Keith Grossman	director, officer: President & CEO
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Michael F Demane	director, officer: Chief Executive Officer	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Niamh Louise Pellegrini	officer: Chief Commercial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Brad Vale	director	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Susan E Siegel	director	3000 SAND HILL ROAD, BLDG 3 STE 290, MENLO PARK CA 94025
Roderick H. Macleod	officer: Chief Financial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Patrick Schmitz	officer: Vice President, Operations	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065